The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients

PURPOSE: Diabetes increases the risk of fragility fractures. As a result, when choosing a diabetes treatment, whether the drug affects bone density should be taken into account. The goal of this study was to determine how switching from dipeptidyl peptidase-4 inhibitors (DPP-4i) to glucagon-like pep...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chun-Feng, Mao, Tso-Yen, Hwang, Shinn-Jang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843232/
https://www.ncbi.nlm.nih.gov/pubmed/36760582
http://dx.doi.org/10.2147/DMSO.S389964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843232/
https://www.ncbi.nlm.nih.gov/pubmed/36760582
http://dx.doi.org/10.2147/DMSO.S389964

Ejemplares similares